Treatment Guide

Kybella

Also known as: ATX-101, Deoxycholic Acid Injection, Belkyra (Canada/Europe), Double Chin Injection

Kybella is the only FDA-approved injectable treatment for submental fat reduction — it uses synthetic deoxycholic acid, a bile acid naturally produced by the body to break down dietary fat, to permanently destroy fat cells under the chin. Most patients need 2–4 sessions spaced 4 weeks apart, with results that are permanent for destroyed fat cells.

Vera helps you research Kybella with clinical clarity — AI analysis, real patient outcomes, and verified providers near you.

Download the App
Treatment typeInjectable Fat Reduction (Deoxycholic Acid)
ManufacturerAllergan Aesthetics / AbbVie
Active ingredientSynthetic deoxycholic acid (10 mg/mL); a cytolytic agent that disrupts adipocyte cell membranes
Results timelineVisible reduction begins after 4–6 weeks as swelling resolves and fat is metabolized; full results at 12 weeks after final session
How long results lastPermanent — destroyed fat cells do not regenerate; results maintained with stable weight
Sessions typical2–4 sessions (up to 6 per FDA approval) spaced minimum 4 weeks apart
Pain level  3 / 5 (burning and stinging during and after injection; significant post-injection discomfort)
Average cost (US)$1,200–$1,800 per session (price includes number of vials used; varies by volume of fat)
Downtime5–14 days significant swelling, bruising, and hardness per session
US FDA statusFDA BLA 206333[3]  ·  Approved April 29, 2015  ·  Indication: improvement in the appearance of moderate-to-severe convexity or fullness associated with submental fat

How does Kybella work?

Kybella's active ingredient is deoxycholic acid (DCA) — a secondary bile acid produced endogenously by the body to emulsify and absorb dietary fat in the intestine. When injected directly into subcutaneous fat tissue, synthetic deoxycholic acid acts as a cytolytic agent: it disrupts the phospholipid bilayer of adipocyte (fat cell) membranes, causing rapid cell lysis and death[2].

The destroyed fat cells and their released lipids are then cleared by macrophages as part of the inflammatory wound-healing response over 4–12 weeks following each treatment session. This phagocytic clearance of lysed adipocytes is the mechanism through which the visible fat reduction occurs — the body literally digests and removes the destroyed cells. Once destroyed, mature adipocytes in the treated area do not regenerate.

In FDA pivotal clinical trials (REFINE-1 and REFINE-2), 82.4% of Kybella-treated patients showed at least a 1-grade improvement[4] in submental fullness on the validated Clinician Reported Submental Fat Rating Scale, compared to 18.5% of placebo-treated patients — across a combined 1,022 subjects.

Unlike surgical liposuction — which mechanically removes fat cells — or cryolipolysis (CoolSculpting) — which induces apoptosis via freezing — Kybella uses chemical lysis. The advantage is precision of injection placement; the disadvantage is the significant inflammatory response (swelling, hardness) that follows each session as the body processes the destroyed cells.

What does Kybella treat, and who is it for?

Kybella is FDA-approved exclusively for the reduction of moderate-to-severe submental fat — the adipose tissue directly beneath the chin that creates the appearance of a "double chin." Submental fat is largely genetic in distribution and often resistant to diet and exercise, making it a source of frustration for many patients who are otherwise lean.

The ideal Kybella candidate has moderate-to-severe submental fat fullness (grade 2–4 on the 5-point Submental Fat Rating Scale), adequate skin elasticity (patients with significant skin laxity may achieve fat reduction but see insufficient skin tightening to complement the result), and realistic expectations about the gradual, swelling-heavy nature of the process.

Off-label uses include treatment of small pockets of localized fat in the jowl area, bra fat (axillary rolls), and other areas of focal adiposity. These uses are supported by the mechanism of action but lack FDA approval and require clinical experience to perform safely given the importance of avoiding adjacent structures (nerves, salivary glands in the submental area specifically).

In a patient-reported outcome survey from the REFINE trials, 72.6% of Kybella patients reported an improvement in psychological impact of their submental fullness — including feeling less bothered and more satisfied with their facial appearance — compared to 15.4% of placebo patients at week 12 post-final treatment.

What happens during a Kybella procedure?

Prior to injection, the provider marks the submental area using a mapping grid — pre-printed grids are available that account for the anatomy of the marginal mandibular nerve branch (a critical structure that must be avoided to prevent temporary or permanent weakness of the lower lip depressor muscles). The grid identifies 0.5–1.0 cm spacing between injection points.

  1. Marking and safety assessment: The marginal mandibular nerve's approximate course is identified and the injection-free zone (superior to the mandible) is marked. The distribution of submental fat is assessed by pinching to estimate volume and depth.
  2. Topical numbing: Ice and/or topical anesthetic is applied. Some providers administer a small volume of dilute lidocaine into the submental area before Kybella injection to reduce burning.
  3. Grid injection: Kybella (2 mg/cm²) is injected at multiple points across the marked grid using a 30-gauge needle — typically 20–50 injections per session. Each injection delivers 0.2 mL at 1–1.5 cm depth directly into subcutaneous fat.
  4. Post-injection: Ice packs are applied immediately. Patients experience a burning, stinging sensation that typically peaks within the first hour and subsides over several hours. Significant swelling begins within 1–4 hours and peaks over 24–72 hours.
  5. Recovery monitoring: Providers assess patients at the next scheduled session (minimum 4 weeks) for residual induration (hardness), nerve effects, and degree of fat reduction before deciding whether additional treatment is warranted.

What results can I expect from Kybella?

Kybella results are gradual and progressive — patients do not see immediate fat reduction, as the destroyed fat cells must be cleared by the immune system over 4–12 weeks. After each session, the area goes through a predictable recovery arc: significant swelling (which temporarily makes the submental area appear larger before clearing), followed by hardness as fibrosis forms, then gradual softening and visible reduction.

Most patients see meaningful fat reduction after 2 sessions, with optimal results after 3–4 sessions. The full result of any given session is evaluated at the next appointment (4 weeks minimum) to decide whether additional treatment is needed. Patients who respond well to the first session tend to require fewer total sessions.

The final result — after all sessions and complete resolution of post-treatment inflammation — is a visibly slimmer chin profile with improved jawline definition. Patient satisfaction in clinical trials is high among those who complete the full treatment series, with the majority reporting they would recommend the treatment to others.

Not sure if Kybella is right for you?

Vera's AI Aesthetician analyzes your facial structure and builds a personalized treatment plan for your specific concerns — not a generic quiz, an actual analysis.

Get My Facial Analysis

What is the recovery and downtime after Kybella?

Kybella has the most significant post-treatment recovery of any widely used facial injectable treatment. The inflammatory response necessary for fat cell clearance produces predictable but substantial temporary side effects after each session.

Days 1–3: Significant swelling, redness, and warmth in the submental area. The area may feel hot and tender to touch. The chin may appear larger than pre-treatment due to edema. Some providers advise patients to plan that they will look "like they have a frog under their chin" for several days.

Days 3–14: Swelling begins to gradually subside, but the area remains firm and indurated (hard) as fibrosis forms — this hardness is a normal part of healing and eventually resolves. Numbness or altered sensation in the submental area is common and may persist for several weeks to months. Bruising resolves within 1–2 weeks.

Most patients plan to avoid important social or professional events for 1–2 weeks after each Kybella session. Because multiple sessions are required, patients should factor in the cumulative recovery periods when planning their treatment timeline.

What are the risks and side effects of Kybella?

Expected side effects — swelling, bruising, pain, numbness, redness, and areas of hardness — are near-universal and part of the intended treatment mechanism. These resolve over weeks. Prolonged numbness (beyond 6–8 weeks) and persistent induration are uncommon but should prompt provider follow-up.

The most clinically significant risk is marginal mandibular nerve injury — occurring in approximately 4% of patients in clinical trials. This manifests as asymmetric smile or weakness of lower lip movement, is typically temporary (resolves within 6 weeks on average), and is minimized by careful injection placement below the mandible. Permanent nerve injury is extremely rare.

Alopecia (hair loss) in the submental area has been reported when Kybella is injected at too superficial a depth, affecting hair follicles. Skin ulceration and necrosis are rare adverse events reported with off-label use. Patients with dysphagia (swallowing difficulty) should not be treated in the submental area.

How much does Kybella cost?

Kybella pricing is variable based on the number of vials used per session, which depends on submental fat volume.

  • United States — per vial (2 mL): $600–$900
  • United States — per session (2–4 vials): $1,200–$3,600
  • United States — typical course (2–4 sessions): $2,400–$7,200

A complete Kybella course cost is comparable to or higher than surgical liposuction for submental fat removal — liposuction produces more immediate results with a single procedure but carries surgical risks and anesthesia. For patients who prefer a non-surgical approach, Kybella offers a meaningful alternative with permanent fat destruction and no ongoing retreatment needed once the desired result is achieved.

Despite its higher price point compared to some non-surgical alternatives, Kybella is the only FDA-approved injectable specifically indicated for submental fat — and its permanent fat destruction means no ongoing retreatment is needed for patients who achieve their desired result and maintain stable weight.

Kybella vs. CoolSculpting Mini vs. Liposuction

How Kybella compares to the main alternatives for submental fat reduction.

Kybella CoolSculpting Mini Submental Liposuction
Mechanism Deoxycholic acid chemically lyses fat cell membranes → cells cleared by macrophages Cryolipolysis — controlled cooling causes fat cell apoptosis over 4–12 weeks Surgical mechanical removal of fat cells via cannula under anesthesia
Sessions 2–4 sessions, 4 weeks apart (up to 6 FDA-approved) 1–3 sessions, 6–8 weeks apart Single procedure
Results onset 4–12 weeks after each session; progressive 4–12 weeks after each session; progressive Immediately visible; full result at 3–6 months as swelling resolves
Permanence Permanent for destroyed cells; weight gain can enlarge remaining cells Permanent for destroyed cells; same caveat Permanent; most definitive fat reduction
Downtime 5–14 days significant swelling per session 1–2 weeks firmness and numbness; less visible swelling than Kybella 1–2 weeks primary recovery; full recovery 4–6 weeks
Risks Marginal mandibular nerve injury (temporary ~4%); swelling, bruising, numbness Paradoxical adipose hyperplasia (rare); numbness, firmness Surgical risks (bleeding, infection, anesthesia); contour irregularities
Cost (US) $1,200–$1,800 / session; $2,400–$7,200 total course $750–$1,500 / session; $750–$4,500 total course $3,000–$7,000 total (single procedure)

See real Kybella results from verified providers on Vera →

Frequently asked questions about Kybella

Evidence-based answers to the most common questions about deoxycholic acid injection for double chin reduction.

How many Kybella treatments are needed?

Most patients require 2–4 Kybella treatment sessions spaced at least 4 weeks apart. FDA clinical trials showed that up to 6 sessions were required for some patients to achieve their desired result. The number of sessions depends on the volume of submental fat, the desired reduction, and individual response to deoxycholic acid. After achieving optimal results, no retreatment is needed in most cases because the destroyed fat cells do not regenerate.

Is Kybella permanent?

Yes — Kybella results are considered permanent because deoxycholic acid destroys fat cells permanently. Once adipocytes are destroyed, they cannot regenerate. However, if the patient gains significant weight after treatment, remaining untreated fat cells in the submental area can enlarge and the appearance of a double chin may return. Maintaining stable weight preserves Kybella results indefinitely.

What is the downtime after Kybella?

Kybella has significant temporary downtime compared to other injectable treatments. Immediately after treatment, the submental area swells significantly — the swelling typically peaks at 24–72 hours and can be pronounced. Most patients experience 5–14 days of visible swelling, redness, bruising, and hardness in the treated area. Numbness or altered sensation may persist for several weeks. Patients should plan for this downtime and avoid important social events for 1–2 weeks after each session.

Does Kybella hurt?

The Kybella injection procedure itself involves a grid of 20–50 small injections in the submental area. Topical numbing cream is applied beforehand and the product contains lidocaine, which helps manage discomfort during and immediately after injection. After the lidocaine wears off (within 1–2 hours), patients typically experience a burning, stinging sensation in the treated area that can persist for hours to days. This post-injection discomfort is the most commonly reported aspect of the Kybella experience.

How does Kybella compare to CoolSculpting for the double chin?

Both Kybella and CoolSculpting Mini are FDA-approved for submental fat reduction but use different mechanisms. Kybella uses deoxycholic acid to chemically destroy fat cells; CoolSculpting Mini uses cryolipolysis (controlled freezing) to cause fat cell apoptosis. Kybella requires 2–4 sessions with 1–2 weeks of significant downtime per session; CoolSculpting Mini requires 1–3 sessions with 1–2 weeks of firmness and numbness but less visible swelling. Results from both are permanent for destroyed fat cells. CoolSculpting Mini may be preferred by patients wanting to minimize visible post-treatment swelling.

Still have questions about Kybella? Vera's AI Aesthetician doesn't give generic answers — it analyzes your specific skin profile, concerns, and goals to tell you what's actually relevant for you.

Get My Personalized Treatment Plan →

Your guide to science-backed beauty treatments.

Built by experts of clinical K-Beauty

4.6★  ·  25 ratings on the App Store

★★★★★

Cut through the noise

"Vera is the first app that actually helped me make sense of it all. It's like having a knowledgeable friend who's done all the homework. Game changer."

Mlymat · January 2026

Sources

  1. Ascher B, Hoffmann K, Walker P, Lippert S, Wollina U, Havlickova B. Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid) in the treatment of submental fat: results from a phase III, randomized, placebo-controlled trial. Journal of the European Academy of Dermatology and Venereology. 2014;28(12):1707-1715. PubMed ↗
  2. Rzany B, Griffiths T, Walker P, Lippert S, McDiarmid J, Havlickova B. Reduction of unwanted submental fat with ATX-101 (deoxycholic acid) in a randomized, placebo-controlled study. British Journal of Dermatology. 2014;170(2):445-453. PubMed ↗
  3. Allergan Aesthetics. KYBELLA (deoxycholic acid) injection Prescribing Information. US Food and Drug Administration. 2020. FDA ↗
  4. Jones DH, Carruthers J, Joseph JH, et al. REFINE-1, a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial with ATX-101, an injectable drug for submental fat reduction. Dermatologic Surgery. 2016;42(1):38-49. PubMed ↗